BAAR, Switzerland–(BUSINESS WIRE)–Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc. (“Astellas”), AstraZeneca and Bristol Myers Squibb to accelerate their global clinical development using Evinova’s AI-native platform. Each partner company has opted in to share operational data with Evinova, enabling the platform to provide benchmarks and smarter recommendations intended to further accelerate clinical trials and improve patient outcomes.
Reimagining Clinical Development Through Collaboration
Clinical development is often slowed by fragmented systems and manual processes that delay timelines and increase costs. Evinova’s AI-native platform addresses these challenges through intelligent optimization, faster end-to-end workflows and recommendations for improvements. The platform, now enhanced with multi-agent AI capabilities, empowers partners to innovate, adapt, and achieve better outcomes.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “This strategic collaboration with Evinova harnesses AI to accelerate clinical development, which we believe will significantly improve productivity gains, deliver faster trials, and enhance patient experience. More broadly, the AI-era will empower us to demonstrate the continued excellence of our science and the benefits it can deliver, fundamentally improving patient care in clinical development and helping us to deliver new medicines.”
Tadaaki Taniguchi, MD, PhD, Chief Research & Development Officer at Astellas, said: “At Astellas, we view AI as a practical catalyst for accelerating clinical development, enabling us to bring innovative medicines to patients faster. By partnering with Evinova and leveraging their AI-native Study Designer platform, our teams will be able to design smarter, more patient centered studies, eliminate avoidable rework, and move with greater speed and precision as we pioneer science in breakthrough areas of R&D.”
Cristian Massacesi, MD, EVP, Chief Medical Officer & Head of Development at Bristol Myers Squibb, said: “Transforming clinical development is not just an opportunity; it is an urgent necessity. For years, developing medicines has taken too long, cost too much money, and mostly resulted in failure. Digital tools and AI can help us overcome these limitations and lay the foundation for better health outcomes for countless individuals in the years to come. The decisions we make now will shape the future of medicine, accelerate progress and ensure that the benefits of scientific advancement reach those who need them most.”
Cristina Duran, President of Evinova, said: “At Evinova, our mission is to drive meaningful transformation in clinical development for sponsors, sites, and patients. By uniting deep domain expertise with the power of AI, our strategic collaborations with life science leaders are moving the industry from heavy manual, fragmented processes to intelligent, AI-first workflows that deliver measurable benefits at scale.”
Proven Impact for Life Science Leaders
Evinova’s AI-native platform accelerates clinical development while ensuring the user has full control of decision making, supporting compliance and confidence across every phase of the trial lifecycle. The globally scaled platform features a flexible architecture that enables a multi-model partner approach, provides access to the most advanced AI models and trained agents with deep enterprise expertise as well as smarter operational insights through an opt-in data sharing mechanism. Evinova’s platform has delivered transformative value, unlocking 5 to 7 percent savings minimum per study, adding to hundreds of millions of dollars for top 10 pharma across their portfolio.
Key platform products driving substantial value include:
- Evinova Study Designer: AI-driven, scenario-based study design capabilities enable teams to create and review study designs in minutes and compare against benchmarks, allowing users to analyze implications and optimize cost, timelines, patient experience, and carbon emissions.
- Evinova AI Authoring: A single clinical trial requires 200+ interconnected document types. Evinova’s AI agents provide intelligent authoring recommendations trained on regulatory, operational, scientific, quality and patient-centric inputs, augmenting teams with enterprise learnings and curated external data. This reduces costly protocol amendments, which drives significant savings opportunities and accelerates timelines.
- Evinova AI Digitizer: Converts clinical study designs, protocols and documents into machine-readable formats using agentic AI, establishing a backbone of the Clinical Data Interchange Standards Consortium (CDISC) Unified Study Definitions Model (USDM) 4.0 standards. This creates a reusable digital backbone for downstream process automation to accelerate study start-up.
The platform’s modular, cloud-native architecture ensures real-time collaboration and high-performance computing. Organizations can integrate proprietary AI models with built-in privacy safeguards and compliance across global markets.
Partner with Us to Advance Clinical Development
Evinova invites forward-thinking organizations to join us in redefining a future where clinical development is faster, more efficient, and truly patient-centric. Pharma, biotech and contract research organizations (CROs) interested in working with us can reach out here.
About Evinova
Evinova empowers life science leaders to accelerate better health outcomes. Purpose-built by healthcare for healthcare, Evinova delivers intelligently designed digital and AI-native solutions that optimize the entire clinical development lifecycle from end to end. With proven outcomes published in Nature Medicine, Evinova’s solutions and strategies have demonstrated up to 60% improvement in patient experience, 6-month acceleration in trial delivery, and 32% reduction in costs. Evinova is a separate health tech company within the AstraZeneca group. Learn more about Evinova at www.evinova.com or on social media @Evinova.
Contacts
Media Contact:
Heather Bonsiero
Director of Communications and Marketing
Evinova
[email protected]
